DOCSLIB.ORG

Contrast Agents for Liver MR Imaging

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Contrast Agents for Liver MR Imaging 3 Contrast Agents for Liver MR Imaging CONTENTS tra-hepatic abdomen [15]. However, until the ad- vent of multi-detector CT (MDCT), the value of 3.1 Introduction conventional CT for the characterization of focal 3.1.1 Non-Specific Gadolinium Chelates liver lesions was generally considered to be inferior 3.1.2 Hepatocyte-Targeted Contrast Agents to that of contrast-enhanced magnetic resonance 3.1.3 Agents with Combined Extracellular and imaging (MRI) [123]. With the recent develop- Hepatocyte-Specific Distribution ments in MDCT technology, particularly the emer- 3.1.4 RES-Specific Contrast Agents gence of 16- and 64-row scanners combined with 3.2 Injection Schemes for Liver MRI with highly concentrated iodinated contrast agents, the Different Contrast Agents impact of CT in both detection, and to a lesser ex- 3.3 Radiologic Classification of Focal Liver tent, characterization of focal liver lesions has Lesions on Unenhanced and Contrast- markedly improved [30, 61, 117]. In particular, CT Enhanced MRI has substantially shorter acquisition times, the pos- 3.4 Summary sibility to acquire thin sections on a routine basis within a single breath-hold, the opportunity to ret- rospectively calculate thinner or thicker sections from the same raw data, and improved 3D-postpro- cessing techniques. These features now permit the 3.1 acquisition of similar diagnostic information to Introduction that attainable on contrast-enhanced MRI with conventional extracellular gadolinium contrast The imaging evaluation of patients with suspected agents, where information derives from differential liver masses has three principal purposes: blood flow between the tumor and surrounding • lesion detection, normal liver parenchyma. However, unlike the situ- • lesion characterization, ation in MRI, there are as yet no hepatospecific • evaluation of the intra- and extrahepatic extent contrast agents available for CT. Hence, additional of tumor. information based on the functionality of liver le- All three of the major non-invasive imaging sions, which is attainable with MRI, is not yet at- modalities have roles to play in liver imaging. tainable with MDCT. Moreover, concern over the Ultrasound (US) has traditionally been used for nephrotoxicity of certain iodinated contrast agents the primary screening of patients with abdominal [128] and the requisite use of ionizing radiation in pain, but the advent of contrast-enhanced US tech- CT examinations are factors which should always niques now makes it a highly capable methodology be considered when referring patients for diagnos- for both the characterization and improved detec- tic evaluation of the liver. tion of liver masses [60, 93]. Computed tomogra- In contrast to the situation in CT,several differ- phy (CT) has generally been considered the imag- ent classes of contrast agent are available for rou- ing approach of choice for the detection of liver tine clinical use in MRI of the liver [39, 43, 70, 105, masses principally because of the ease of perform- 122]. These include non-specific materials that dis- ing and interpreting large numbers of examina- tribute extracellularly in a manner similar to that tions, its widespread availability, and its generally of the iodinated agents used in CT, materials that acknowledged superior ability to evaluate the ex- are taken up specifically by hepatocytes and ex- 54 MRI of the Liver creted in part through the biliary system, and ma- 147]. The four non-specific gadoliniumchelates ap- terials that are targeted specifically to the Kupffer proved in the USA are gadopentetate dimeglumine cells of the reticuloendothelial system (RES) (Ta- (Magnevist®, Gd-DTPA; Berlex Laboratories/Scher- bles 1, 2). The differential use of these agents, de- ing AG), gadoteridol (ProHance®, Gd-HP-DO3A; pending on the clinical purpose, can maximize the Bracco Diagnostics), gadodiamide (Omniscan®, Gd- diagnostic information available to the investigat- DTPA-BMA; GE Healthcare), and gadoversetamide ing radiologist. This chapter describes the proper- (Optimark®, Gd-DTPA-BMEA; Mallinckrodt). Other ties and indications for each category of contrast non-specific gadolinium agents currently approved agent for MRI of the liver. only in Europe include gadoterate meglumine (Dotarem®, Gd-DOTA; Guerbet) and gadobutrol (Gadovist®, Gd-BT-DO3A; Schering AG) (Table 2). 3.1.1 Although the safety profiles of these agents are all Non-Specific Gadolinium Chelates extremely attractive, especially in comparison to io- dinated x-ray contrast agents [39, 54, 70, 79, 80, 82, Chelates of the paramagnetic gadolinium ion that 105, 107, 127, 132], possible problems associated distribute solely to the extracellular space (i.e. do with the least stable of these agents (gadodiamide not have any tissue-specific biodistribution) have and gadoversetamide) [54] have recently come to been commercially available since 1986 [113, 136, light. Specifically, both gadodiamide and gadoverse- Table 1. Contrast agent type Manufacturer Principal Mechanism Extracellular Gd agents Gadopentetate dimeglumine; Gd-DTPA (Magnevist®) Schering1 / Berlex2 T1 shortening Gadoteridol; Gd-HP-DO3A (ProHance®) Bracco3 ,4 T1 shortening Gadodiamide; Gd-DTPA-BMA (Omniscan®) GE Healthcare5 T1 shortening Gadoversetamide; Gd-DTPA-BMEA (OptiMARK®) Tyco Healthcare6 T1 shortening Gadoterate meglumine; Gd-DOTA (Dotarem®) Guerbet7 T1 shortening Gadobutrol; Gd-BT-DO3A (Gadovist®) Schering1 T1 shortening Hepatobiliary agent Mangafodipir trisodium; Mn-DPDP (Teslascan®) GE Healthcare5 T1 shortening Combined extracellular / hepatobiliary agents Gadobenate dimeglumine; Gd-BOPTA (MultiHance®) Bracco3 ,4 T1 shortening Gadoxetate; Gd-EOB-DTPA (Primovist®) Schering1 / Berlex2 T1 shortening SPIO agent AMI-25; Ferumoxides (Feridex®; Endorem®) Berlex8 / Guerbet7 T2 shortening USPIO agents SH U 555 A (Resovist®) Schering1 T1 & T2 shortening AMI-227 (Combidex®; Sinerem®) Advanced Magnetics8 / T1 & T2 shortening Guerbet7 1 = Berlin, Germany; 2 = Wayne NJ, USA; 3 = Milano, Italy; 4 = Princeton NJ, USA; 5 = Chalfont St. Giles, UK; 6 = St. Louis MO, USA; 7 = Aulnay- Sous-Bois, France; 8 = Cambridge MA, USA Table 2. Physicochemical characteristics of commercially-available T1-shortening MR contrast agents Characteristic Extracellular agents Combined extracellular / Hepatobiliary hepatobiliary agents agent Magnevist ProHance Omniscan OptiMARK Dotarem Gadovist MultiHance Primovist Teslascan (0.5 mol/L) (0.5 mol/L) (0.5 mol/L) (0.5 mol/L) (0.5 mol/L) (1.0 mol/L) (0.5 mol/L) (0.2 5 mol/L) (0.0 5 mol/L) Molecular structure Linear, Cyclic, Linear, Linear, Cyclic, Cyclic, Linear, Linear, Not applicable ionic non-ionic non-ionic non-ionic ionic non-ionic ionic ionic Thermodynamic stability 22.123.816.916.625.821.822.623.4 Not applicable constant (log Keq) Conditional stability 18.117.114.915.018.8 N/A 18.418.7 Not applicable constant at pH 7.4 Osmolality (Osm/kg) 1.96 0.63 0.65 1.11 1.35 1.61.97 0.69 0.30 3 • Contrast Agents for Liver MRImaging Liver for Agents 3 •Contrast 55 Viscosity (mPa•s at 37°C) 2.91.31.42.02.04.96 5.31.19 0.8 r1 relaxivity 0.2 T 4.7a NA NA NA NA 5.5 a 10.9a NA NA in plasma 0.47 T 4.8b, 3.8c, 4.9d 4.9b , 4.8c 4.4b , 4.4c 5.7c 4.3c 5.6b , 6.1c 9.2c, 9.7d 8.7c, 8.7e 3.6c (L/mmol•s–1) 1.5 T 3.9a, 4.1c 4.1c 4.3c 4.7c 3.6c 4.7a, 5.2c 8.1a, 6.3c 6.9c 3.6c 3 T 3.3a, 3.7c 3.7c 4.0c 4.5c 3.5c 3.6a, 5.0c 6.3a, 5.5c 6.2c 2.7c r2 relaxivity 0.2 T 9.6a NA NA NA NA 10.1 a 18.9a NA NA in plasma 0.47 T 4.1c, 6.3d 6.1c 4.6c 5.7c 5.5c 7.4c 12.9c, 12.5d 13.0c, 8.7e 4.3c (L/mmol•s–1) 1.5 T 5.3a, 4.6c 5.0c 5.2c 6.6c 4.3c 6.8a, 6.1c 18.7a, 8.7c 8.7c 7.1c 3 T 5.2a, 5.2c 5.7c 5.6c 5.9c 4.9c 6.3a, 7.1c 17.5a, 11.0c 11.0c 9.3c NA = not available ; a = Pintaske et al [88].; b = Vogler et al [141]; c = Rohrer et al.[100]; d = De Haen et al.[20], e = Schuhmann-Giampieri [119] n.b. r1 and r2 relaxivity values from Rohrer et al. were determined from curves of relaxation rate versus concentration for just two concentrations of contrast agent and hence are subject to variability. Values from Pintaske et al. were determined for a minimum of eight contrast agent concentrations. 56 MRI of the Liver tamide, but none of the other approved gadolinium since most focal lesions, especially primary liver agents, have been shown to cause spurious hypocal- tumors like hepatocellular carcinoma (HCC) and cemia as a result of interference with laboratory metastases are supplied primarily via the hepatic tests for serum calcium [25, 54, 71, 90, 91]. The issue arteries [41, 72, 148]. Enhancement during the ar- of gadolinium chelate stability in the case of gado- terial dominant phase is important in order to de- diamide has also been raised in a study to deter- tect perfusion abnormalities. For example, tran- mine the extent to which gadolinium is deposited in sient increased segmental enhancement in liver bone following intravenous injection of this agent segments may indicate that portal-venous flow is [33]. compromised due to compression or thrombosis As paramagnetic compounds, gadolinium [114, 152]. This can be of value in patients where chelates shorten T1 tissue relaxation times when findings on unenhanced images are equivocal. injected intravenously. At recommended doses of Typically, maximal enhancement of the hepatic 0.1-0.3 mmol/kg their principal effect is to shorten parenchyma is seen in the portal-venous phase. In the T1 relaxation time resulting in an increase in this phase, hypovascular lesions such as cysts, hy- tissue signal intensity.
Load more

Recommended publications
  • Theranostics and Contrast Agents for Magnetic Resonance Imaging Yohan Jeong, Hee Sook Hwang and Kun Na*
    Jeong et al. Biomaterials Research (2018) 22:20 https://doi.org/10.1186/s40824-018-0130-1 REVIEW Open Access Theranostics and contrast agents for magnetic resonance imaging Yohan Jeong, Hee Sook Hwang and Kun Na* Abstract Background: Magnetic resonance imaging is one of the diagnostic tools that uses magnetic particles as contrast agents. It is noninvasive methodology which provides excellent spatial resolution. Although magnetic resonance imaging offers great temporal and spatial resolution and rapid in vivo images acquisition, it is less sensitive than other methodologies for small tissue lesions, molecular activity or cellular activities. Thus, there is a desire to develop contrast agents with higher efficiency. Contrast agents are known to shorten both T1 and T2. Gadolinium based contrast agents are examples of T1 agents and iron oxide contrast agents are examples of T2 agents. In order to develop high relaxivity agents, gadolinium or iron oxide-based contrast agents can be synthesized via conjugation with targeting ligands or functional moiety for specific interaction and achieve accumulation of contrast agents at disease sites. Main body: This review discusses the principles of magnetic resonance imaging and recent efforts focused on specificity of contrast agents on specific organs such as liver, blood, lymph nodes, atherosclerotic plaque, and tumor. Furthermore, we will discuss the combination of theranostic such as contrast agent and drug, contrast agent and thermal therapy, contrast agent and photodynamic therapy, and neutron capture therapy, which can provide for cancer diagnosis and therapeutics. Conclusion: These applications of magnetic resonance contrast agents demonstrate the usefulness of theranostic agents for diagnosis and treatment.
    [Show full text]
  • Harmonised Bds Suppl 20070
    ABCDEF 1 EU Harmonised Birth Dates and related Data Lock Points, Supplementary list, 7 February 2007 Innovator brand name First DLP after Proposed Active substance name (INN) (for fixed combination 30 October Firm's Name Comments EU HBD products only) 2005 2 3 Aceclofenac 19900319 20080331 Almirall / UCB 4 Aciclovir 19810610 20060630 GSK 5 Adrafinil 19810710 20060131 Cephalon 6 Aldesleukine 19890703 20051231 Novartis NL=RMS Pfizer/Schwarz 7 Alprostadil (erectile dysfunction) 19840128 20080131 Pharma UK=RMS Alprostadil (peripheral arterial 19810723 20060731 Pfizer product differs from Schwarz Pharma 8 occlusive diseases) product Alprostadil (peripheral arterial 19841128 20051128 Schwarz Pharma product differs from Pfizer product 9 occlusive diseases) 10 Atenolol + chlorthalidone Tenoretic 19970909 20080908 AstraZeneca Azelaic acid 19881027 20060102 Schering AG / Pfizer AT = RMS 11 12 Aztreonam 19840804 20060803 BMS 13 Benazepril 19891128 20071130 Novartis Benazepril + hydrochlorothiazide Cibadrex 19920519 20070531 Novartis 14 15 Bisoprolol 19860128 20070930 Merck AG Bisoprolol + hydrochlorothiazide many product names 19920130 20061103 Merck AG 16 17 Botulinum Toxin A 19960906 20061030 Allergan currently 6-monthly PSURs 18 Brimonidine 19960906 20080930 Allergan UK=RMS 19 Brimonidine + timolol Combigan 19960906 20080930 Allergan UK=RMS 20 Bromperidol 20061115 J&J 21 Brotizolam 19830515 20071231 Boehringer Ingelheim 22 Budesonide 19920430 20070430 AstraZeneca 23 Budesonide + formoterol Symbicort 20000825 20070825 AstraZeneca 24 Buflomedil
    [Show full text]
  • ACR Manual on Contrast Media
    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Active Moiety Name FDA Established Pharmacologic Class (EPC) Text
    FDA Established Pharmacologic Class (EPC) Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: Active Moiety Name “(Drug) is a (FDA EPC Text Phrase) indicated for [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • Mangafodipir Trisodium) Injection 37.9 Mg/Ml (50 Μmol/Ml)
    PRODUCT MONOGRAPH TESLASCAN* (mangafodipir trisodium) Injection 37.9 mg/mL (50 µmol/mL) For intravenous injection only Contrast Enhancement Agent for Magnetic Resonance Imaging (MRI) GE Healthcare Canada Inc. Date of Preparation: 2300 Meadowvale Blvd., November 23, 2006 Mississauga, Ontario, L5N 5P9 Control # 110005 *Trade Mark PRODUCT MONOGRAPH TESLASCAN* (mangafodipir trisodium) injection 37.9 mg/mL (50 µmol/mL) For intravenous injection only THERAPEUTIC CLASSIFICATION Contrast Enhancement Agent for Magnetic Resonance Imaging (MRI) ACTION AND CLINICAL PHARMACOLOGY TESLASCAN Injection (mangafodipir trisodium) is a complex formed between a chelating agent (fodipir) and a metal ion, manganese, which has paramagnetic properties and is responsible for the contrast enhancement effect in MRI. Mangafodipir shortens the spin lattice (longitudinal) relaxation time (T1) of targeted tissues during MRI, leading to an increase in signal intensity (brightness) of the tissues. Mangafodipir enhances T1 signal intensity. In a study of 12 healthy volunteer men, mangafodipir began to increase the signal intensity of liver tissue within 1-3 minutes, and steady-state enhancement was reached in about 5-10 minutes. Liver enhancement after TESLASCAN Injection administration is detectable in patients up to 24 hours after injection. After mangafodipir trisodium administration, liver lesions may present in a number of different patterns of contrast enhancement. 1 INDICATIONS AND CLINICAL USE TESLASCAN (mangafodipir trisodium) injection is indicated for intravenous administration as an adjunct to MRI in patients to enhance the T1-weighted images used in the detection, localization, characterization, and evaluation of lesions of the liver. CONTRAINDICATIONS TESLASCAN (mangafodipir trisodium) Injection is contraindicated in patients with known allergic or hypersensitivity reactions to manganese, fodipir or any of the inert ingredients.
    [Show full text]
  • Environmentally Classified Pharmaceuticals 2014-2015
    2014-2015 ENVIRONMENTALLY CLASSIFIED PHARMACEUTICALS Stockholm County Council Contents Reducing Residues from Pharmaceuticals in Nature is Part Reducing Residues from Pharmaceuticals of the Environmental Work of in Nature is Part of the Environmental Work of Stockholm County Council ..................1 Stockholm County Council Impact of Pharmaceuticals on Contributing to the reduction of environmental the Environment .........................................................................2 risks from pharmaceuticals is an important part How the Substances are Classified ......................2 of the environmental work of Stockholm County How to Read the Table .................................................4 Council. According to the Environmental Challenge Substances which are Exempt 2016, the Council´s 2012-2016 Environmental from Classification ............................................................6 Programme, the Council is mandated to i.a. do The Precautionary Principle ......................................6 preventive environmental health work. This invol- Tables A Alimentary Tract and Metabolism............................7 ves fostering healthy inhabitants in an environ- ment with clean air and water. To reduce the most B Blood and Blood-Forming Organs ............................9 environmentally hazardous remains of medicinal C Cardiovascular System .................................................10 products in the natural surroundings is therefore D Dermatologicals ............................................................13
    [Show full text]
  • Talking Points on Frequently Asked Questions About Nursing
    Breastfeeding FAQs Talking Points on Frequently Asked Questions about Nursing A Guide for Physicians American Academy of Pediatrics New Jersey Chapter PCORE Breastfeeding FAQs Talking Points on Mothers Frequently Asked Questions about Nursing A Guide for Physicians __________________________________________________________________________________________________________ Diana Mayer MD FAAP IBCLC This book has been reviewed by: Lori Feldman-Winter, MD, MPH Medical Champion, AAPNJ PCORE Baby-Friendly Hospital Initiative Div. Head, Adolescent Medicine Children's Regional Hospital at Cooper Professor of Pediatrics UMDNJ-RWJMS © 2011 American Academy of Pediatrics New Jersey Chapter Talking Points on Mothers Frequently Asked Questions about Nursing TABLE OF CONTENTS Prenatal Questions PAGE Inverted nipples “My nipples are inverted. Will I be able to nurse my infant?”…………………....................... 1 Breast size “My bra cup size is an A. Am I going to have trouble nursing?”……………………………………… 2 Hepatitis B carrier “I am a Hepatitis B carrier. Can I nurse my baby?”………………………………………………………… 2 Hepatitis C carrier “I am a hepatitis C carrier. Can I nurse my baby?”…………………………………………………………. 2 HIV positive mother “I have HIV. Can I nurse my infant?”……………………………………………………………………………… 3 Past history of breast surgery “I had breast surgery in the past. Will I be able to nurse my baby?”………………………………..3 Adoptive Nursing “Can an adoptive mother nurse?”…………………………………………………………………………………. 6 Past Nursing Problems “Breastfeeding did not work with my first child...”………………………………………………………… 7 Family History of atopy “I have lots of food allergies. I was told that this would affect my baby…”…………………….. 9 Nursing and Infant Feeding Behavior Infrequent bowel movements “Mother of a one month old:”My baby has not had a bowel movement in five days.
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • WO 2012/136813 A2 11 October 2012 (11.10.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/136813 A2 11 October 2012 (11.10.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 49/00 (2006.01) A61K 49/10 (2006.01) kind of national protection available): AE, AG, AL, AM, A61B 5/05 (2006.01) A61K 49/18 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 49/04 (2006.01) A61K 49/22 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (21) Number: International Application HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, PCT/EP2012/056363 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 5 April 2012 (05.04.2012) OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (25) Filing Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 201 10544 7 April 201 1 (07.04.201 1) NO GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, (71) Applicant (for all designated States except US): UNI- TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, VERSITETET I OSLO [NO/NO]; Boks 1072, N-03 16 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Blindern (NO).
    [Show full text]
  • Contrast Media Tutorial
    CONTRAST MEDIA TUTORIAL Jessica B. Robbins, MD Myron A. Pozniak, MD For questions, comments, or permission to use any or all of this tutorial, please contact Myron Pozniak MD at [email protected] or 608/263-8312 University of Wisconsin, Department of Radiology, Madison, WI © 2010 Portions of this information are reprinted with permission of the American College of Radiology. No other representation of this material is authorized without expressed, written permission from the ACR. CT CONTRAST AGENTS 1. INTRODUCTION Contrast agents are indispensable in the practice of radiology. Significant improvements in their composition during the past few decades have made them safer and better tolerated, as evidenced by their use in vast numbers of examinations, often in severely ill patients. Nonetheless, risks associated with contrast agents have not been eliminated, and adverse reactions of varying degree continue to occur. Consequently, it is imperative for anybody administering contrast agents to be intimately familiar with the characteristics, indications, and potential side effects of these agents. They must be able to recognize adverse reactions promptly and treat them effectively and rapidly. This tutorial is designed to help residents and practicing physicians utilize contrast agents in a manner that maximizes the safety of their patients. The information reflects policies and practices currently in use in the Radiology Department of the University of Wisconsin. The use of contrast agents should be determined on an individual basis according to the clinical circumstances of each patient. The contents of this tutorial do not guarantee that contrast agents can be used safely in any individual situation, for the decision to use a contrast agent must be made according to the best judgment of the physician in charge of the examination.
    [Show full text]